- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT03019913
Evaluation of Bedside Methods to Measure Muscularity in Critically Ill Patients
Evaluation of Bedside Methods to Measure Muscularity in Critically Ill Patients: A Prospective Observational Study
Muscle wasting is a significant problem in critically ill patients, with reported losses of a half to three percent per day over the first ten days (for an average 70kg person this equates to 3 to 20kg of muscle loss). Low skeletal muscle mass at admission to the intensive care unit (ICU) and the loss of lean tissue have been associated with negative clinical outcomes, including increased incidence of infections, length of stay, mortality and muscle weakness. It is therefore crucial that technology is utilised to: 1) identify ICU patients with low muscularity on admission, 2) to help understand the factors impacting muscle loss and to 3) assess the effectiveness of interventions aimed at maintaining skeletal muscle mass in this population.
The measurement of lean body mass in patients admitted to the ICU is challenging however, due to the large fluid shifts that occur in this population and logistical issues in moving patients to specialised machinery for body composition analysis. Currently, there is no validated method for accurately assessing a patient's muscle mass at the bedside in the intensive care setting. It is therefore important to investigate the accuracy, feasibility and reliability of bedside methods such as subjective physical assessment of muscle mass, mid arm muscle circumference, ultrasound and bioimpedance analysis to assess muscularity in this population who are primarily bedbound. In order to do this, a critical comparison is required between these methods and muscularity assessed by a "reference" body composition method, such computed tomography (CT) image analysis. Briefly, quantification of skeletal muscle at the abdomen area utilising abdominal CT images has been shown to be highly representative of whole body skeletal muscle volume.
We wish to conduct a pilot, feasibility study (n= 50), which will recruit patients who have a CT scan (containing abdomen area), performed for clinical purposes. Our primary aim will be to investigate whether muscularity assessed with non-invasive bedside methods (ultrasound, bioimpedance analysis, SGA physical assessment, mid arm muscle circumference) are correlated with skeletal muscle mass quantified by a "reference method" (CT image analysis).
Przegląd badań
Szczegółowy opis
Aim Our primary aim is to investigate whether muscularity assessed via bedside ultrasound is correlated with a reference method for estimating whole body skeletal muscle mass (CT image analysis) in the first few days of critical illness.
Our secondary aims are
- To investigate whether muscularity assessed via other bedside methods (bioimpedance spectroscopy, subjective physical assessment and mid arm muscle circumference) are correlated with a reference method for estimating whole body skeletal muscle mass (CT image analysis) in critically ill patients.
- To better understand the association between measured resting energy expenditure and muscularity in the critically ill.
- To observe changes in skeletal muscle mass (in a sub set of patients who have two CT scans) and the impact various factors, including energy and protein delivery has on these changes.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- The Alfred Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Have had a CT scan of the L3 vertebra performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
Exclusion Criteria:
- CT scan performed >48hrs ago
- Death is imminent or deemed highly likely in the next 96 hours
- Are known to be pregnant
- Treating clinician does not believe the study to be in the best interest of the patient
- It is not possible to image two or more muscle groups via ultrasound (i.e. due to trauma, burns, wounds)
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
---|---|
Mean skeletal muscle mass measured by CT scan analysis at L3 area (cm2)
Ramy czasowe: CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
Mean skeletal muscle mass measured by ultrasound (muscle thickness at each site, cm and rectus femoris CSA, cm2)
Ramy czasowe: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
Miary wyników drugorzędnych
Miara wyniku |
Ramy czasowe |
---|---|
Fat free mass (kg), phase angle and impedance ratio measured by bioimpedance spectroscopy
Ramy czasowe: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
Subjective assessment of muscle and fat wasting via SGA (normal, mild-moderate or severe)
Ramy czasowe: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
Mid arm muscle circumference (cm)
Ramy czasowe: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
Mean skeletal muscle mass measured by CT scan analysis at femoral area (cm2)
Ramy czasowe: CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
Measured resting energy expenditure (kilojoules)
Ramy czasowe: <48 hours after CT scan containing L3 area
|
<48 hours after CT scan containing L3 area
|
Intramuscular, subcutaneous and visceral adipose tissue CSA at L3 area (cm2)
Ramy czasowe: CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
CT performed for clinical reasons ≤24 hours before or ≤72 hours after ICU admission
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Kate Lambell, MNutrDiet, La Trobe University and Alfred Health
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 523/16
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Observational cohort
-
Bristol-Myers SquibbCardioxyl Pharmaceuticals, IncZakończonyNiewydolność sercaStany Zjednoczone
-
Hanoi University of Public HealthKarolinska Institutet; University of Copenhagen; National Children's Hospital,... i inni współpracownicyRekrutacyjnyInfekcja oporna na antybiotyki | Zakażenie Enterobacteriaceae oporne na karbapenemyWietnam
-
AstraZenecaAktywny, nie rekrutującyCOVID-19, SARS-CoV-2Stany Zjednoczone, Belgia, Kanada, Francja, Hiszpania, Dania, Tajlandia, Wietnam, Republika Korei, Zjednoczone Królestwo, Malezja, Izrael, Tajwan, Australia, Niemcy, Polska, Singapur, Zjednoczone Emiraty Arabskie